��������

Calum Sinclair has extensive experience in the field of pharmacovigilance and drug safety. Their most recent role was as the Vice President and Head of Pharmacovigilance at PTC Therapeutics, Inc. Prior to that, they held leadership positions at Shire Pharmaceuticals, serving as the EU Qualified Person for Pharmacovigilance (QPPV) and Head of Benefit-Risk Assessment Scientists. Calum also worked at Cephalon as a Senior Manager in Drug Safety, and at Amgen as a Senior Therapeutic Area Pharmacovigilance Scientist. Calum began their career as a Post-Doctoral Research Scientist at the Medical Research Council. Overall, they have a wide range of experience in various roles within the pharmaceutical industry, particularly in the area of pharmacovigilance and risk management.

Calum Sinclair completed their BSc 2.1. Honours in Biological Sciences at the University of Plymouth from 1990 to 1993. Calum then pursued a PhD in Human Genetics at UCL, which they completed from 1994 to 1998.